Condition

Idiopathic Pulmonary Fibrosis (IPF) clinical trials and research

• 22Clinical trials
• 3NIH research projects
• 1New in 30 days
• 27Countries

Newest Idiopathic Pulmonary Fibrosis (IPF) clinical trials

All recruiting trials (22)

• Nerandomilast in IPF and Progressive Fibrosis: Real-World Data

  This study tests whether nerandomilast helps slow lung function decline in adults with IPF or progressive fibrotic lung disease in routine clinical care.

  Recruiting at 4 sites Tel Aviv Medical Center · Ashkelon and 3 other locations · NCT07919015

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Finger vs. Earlobe Pulse Oximetry During a 6-Minute Walk Test in ILD

  This study tests whether finger or earlobe pulse oximetry gives the same oxygen saturation readings during a 6-minute walk in people with interstitial lung disease.

  Recruiting Hospital de Granollers · Granollers, Spain · NCT07723872

• Biomarker clues for COPD, IPF, and lung cancer

  This study tests whether inflammation, immune, genetic, and epigenetic markers at enrollment can explain how COPD, IPF, or lung cancer present and behave, in order to see if these markers can predict outcomes over a year.

  Recruiting Fondazione Don Carlo Gnocchi ETS · Milan, Milan · NCT07707245

• Inhaled nintedanib powder for IPF in adults

  This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.

  Recruiting Phase 2 Mannkind Corporation · Windsor, Ontario · NCT07679893

• AZD8965 in IPF: see if three doses help IPF patients

  This Phase IIb study tests three doses of AZD8965 against placebo in people with idiopathic pulmonary fibrosis, including those who are and aren’t on antifibrotic therapy.

  Recruiting at 103 sites Phase 2 AstraZeneca · Birmingham, Alabama and 197 other locations · NCT07652658

• Optimizing the diagnostic journey in interstitial lung disease

  This trial tests whether bundling core tests and coordinating appointments can speed up diagnosis for adults referred with suspected interstitial lung disease.

  Recruiting Hospital de Granollers · Granollers, Barcelona · NCT07482917

• Quercetin supplementation for people with fibrotic interstitial lung disease

  This research will try whether taking 500 mg/day of quercetin in two 12-week cycles can change telomere length, reduce signs of cellular aging, and affect lung function in people with IPF and other fibrotic interstitial lung diseases.

  Recruiting University of Crete · Heraklion, Crete · NCT07466420

• TDI01 suspension for treating idiopathic pulmonary fibrosis

  This study will test whether TDI01 suspension helps people with idiopathic pulmonary fibrosis (IPF) and is safe.

  Recruiting Phase 3 Beijing Tide Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT07464912

• BC006 treatment for idiopathic pulmonary fibrosis

  This study will test whether BC006 helps people aged 40 and older with idiopathic pulmonary fibrosis over a 24-week treatment period compared with a placebo.

  Recruiting Phase 2 Dragonboat Biopharmaceutical Company Limited · Shanghai, Shanghai Municipality · NCT07447102

• Measuring body fat and thigh muscle in people with pulmonary fibrosis starting anti-fibrotic drugs

  This project will test whether quick bioelectrical impedance measurements and thigh muscle ultrasound can detect changes in body fat and muscle in adults with IPF or progressive pulmonary fibrosis who are starting anti-fibrotic medications.

  Recruiting Royal Brompton & Harefield NHS Foundation Trust · London · NCT07332117

• Deupirfenidone vs Pirfenidone for IPF in Adults

  This study tests whether deupirfenidone can improve lung function better than pirfenidone in adults with idiopathic pulmonary fibrosis who aren’t on other antifibrotic meds.

  Recruiting at 18 sites Phase 3 PureTech · Palm Spring, California and 17 other locations · NCT07284602

• AP02 (inhaled nintedanib) for idiopathic pulmonary fibrosis

  This trial will test whether inhaled nintedanib (AP02), given twice daily at two different doses, improves lung function and fibrosis measures in adults 40 and older with idiopathic pulmonary fibrosis compared with placebo.

  Recruiting at 49 sites Phase 2 Avalyn Pharma Inc. · Camperdown, New South Wales and 48 other locations · NCT07194382

• Chest CT patterns in rheumatoid arthritis–related interstitial lung disease

  This project will use high-resolution chest CT scans to see if certain lung imaging patterns are linked with rheumatoid arthritis by comparing people with RA, idiopathic pulmonary fibrosis, and other connective tissue diseases.

  Recruiting at 4 sites Azienda Unita Sanitaria Locale di Piacenza · Prague and 4 other locations · NCT07174102

• HEC585 tablets for people with idiopathic pulmonary fibrosis (IPF)

  This trial will test whether HEC585 tablets help adults aged 40 to 80 with idiopathic pulmonary fibrosis (IPF) compared with placebo or the approved drug pirfenidone.

  Recruiting Phase 3 Sunshine Lake Pharma Co., Ltd. · Beijing, Beijing Municipality · NCT07082842

• Testing LTI-03 for treating Idiopathic Pulmonary Fibrosis

  This study is testing a new inhaler medication called LTI-03 to see if it can help people with Idiopathic Pulmonary Fibrosis breathe better and reduce lung damage.

  Recruiting at 45 sites Phase 2 Rein Therapeutics · Birmingham, Alabama and 47 other locations · NCT06968845

• Extension of inhaled antifibrotic treatment with AP01 for pulmonary fibrosis

  This open-label extension lets people with progressive pulmonary fibrosis or IPF who finished a prior Avalyn inhaled-drug study continue taking inhaled pirfenidone (AP01) twice daily to see if they can tolerate and stay on treatment.

  Recruiting at 88 sites Phase 2 Avalyn Pharma Inc. · Birmingham, Alabama and 91 other locations · NCT06951217

• Effects of downhill walking on patients with idiopathic pulmonary fibrosis

  This study is testing if downhill walking can help people with idiopathic pulmonary fibrosis feel better and improve their exercise ability compared to regular walking programs.

  Recruiting Saglik Bilimleri Universitesi · Istanbul, Üsküdar · NCT06756230

• Evaluating SB17170 in patients with idiopathic pulmonary fibrosis

  This study is testing a new drug called SB17170 to see if it can help adults with moderate to severe idiopathic pulmonary fibrosis breathe better over 12 weeks.

  Recruiting at 2 sites Phase 2 SPARK Biopharma · Goyang and 4 other locations · NCT06747923

• Evaluating INS018_055 for Idiopathic Pulmonary Fibrosis

  This study is testing a new oral medication called INS018_055 to see if it is safe and helps adults with Idiopathic Pulmonary Fibrosis feel better.

  Recruiting at 12 sites Phase 2 InSilico Medicine Hong Kong Limited · Birmingham, Alabama and 11 other locations · NCT05975983

• Exploring genetic factors in pulmonary fibrosis

  This study is trying to see if there are genetic links to pulmonary fibrosis by testing family members of patients with the condition for early signs of lung issues.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT03478553

• Collecting biological samples from individuals with and without lung disease

  This study is collecting blood, urine, and airway samples from both healthy people and those with lung diseases to see how their biology differs and learn more about these conditions.

  Recruiting Weill Medical College of Cornell University · New York, New York · NCT01776398

NIH-funded research (3)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Improving IPF care for Veterans with a new, practical care model

  A project to help Veterans with idiopathic pulmonary fibrosis get timely, expert, and age-friendly care using a new care model.

  NIH research Durham VA Medical Center · Durham, United States · NIH-11345476

• New oral medicine targeting a pathway to treat idiopathic pulmonary fibrosis

  This study is looking at a new pill that could help people with idiopathic pulmonary fibrosis (IPF) by targeting a specific pathway in the body, aiming to provide a safer and more effective treatment than what’s currently available.

  NIH research Oncoarendi Therapeutics, LLC · Groton, United States · NIH-11078734

• New treatment targeting IL-17A for idiopathic pulmonary fibrosis

  This study is exploring a new treatment for idiopathic pulmonary fibrosis (IPF) that aims to reduce inflammation in the lungs, which could help improve lung function and quality of life for people living with this condition.

  NIH research Targetsite Therapeutics Corporation · New Haven, United States · NIH-10761365

Related topics

Quick answers

How many Idiopathic Pulmonary Fibrosis (IPF) clinical trials are recruiting right now?

22, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in United States (7 trials), Canada (5 trials), Spain (5 trials), Italy (5 trials), United Kingdom (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →